Technology will be used to develop new vaccines for a variety of diseases.
Novavax licensed a new virus-like particle (VLP) technology from the University of Massachusetts Medical School (UMMS) in Worcester.
The technology was developed in the laboratory of Trudy G. Morrison, Ph.D., professor of molecular genetics and microbiology at UMMS. They used paramyxoviruses as a core for building a VLP vaccine. Parts of the virus are used as a backbone for constructing potentially safer and more effective vaccines.
Under terms of the worldwide, exclusive agreement, Novavax will have the right to use the UMMS technology to develop VLP vaccines for the prevention of any viral diseases in humans. Novavax will make an upfront cash payment, and certain development-based milestones, and royalties on any sales of products developed using the technology.